Independent global B2B platform
Expert in API & CDMO market
Direct contact between you and supplier

Find, compare & contact
Dulaglutide API Manufacturers & Suppliers

Real trade data

Filters

Reset current filters

Type
Production region
Qualifications
Country of origin
Contact suppliers

HIGHLIGHTED

Located in:

China

Produced in:

China

Established in: 2013

MOQ: 1 g

Employees: 25+

ISO9001 certified

Drug R&D center (in Hangzhou)

From lab scale (mg/g) to commercial scale (kgs/tons)

  • CoA

  • GMP

  • CEP

  • FDA

  • USDMF

  • + 0

All certificates

  • CoA

  • MSDS

  • BSE/TSE

  • ISO9001

How does it work?

1
Register for free
icon

You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry

2
Start sourcing
icon

Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only

3
Send inquiries
icon

Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week

4
Get quotation
icon

Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news

5
Arrange agreement
icon

Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module

Looking for Dulaglutide API 923950-08-7?

Description:
Here you will find a list of producers, manufacturers and distributors of Dulaglutide. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Dulaglutide 
Cas Number:
923950-08-7 
DrugBank number:
DB09045 
Unique Ingredient Identifier:
WTT295HSY5

About Dulaglutide

More information about this product: Dulaglutide is a novel glucagon-like peptide-1 agonist (GLP-1) biologic drug consisting of a dipeptidyl peptidase-IV-protected GLP-1 analogue covalently linked to a human IgG4-Fc heavy chain by a small peptide linker. Dulaglutide is indicated in the treatment of type 2 diabetes and can be used once a week. It was approved by the FDA in September 2014. Dulaglutide is manufactured and marketed by Eli Lily under the brand Trulicity™.

It is not known if dulaglutide can increase the risk of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type and is thus not recommended for use in populations with a personal or family history of these conditions.

Do you want to buy this product? Send an inquiry to the listed suppliers that meets your quality requirements.

Dulaglutide is a type of GLP1 agonists


GLP-1 agonists, short for glucagon-like peptide-1 agonists, are a subcategory of pharmaceutical APIs (active pharmaceutical ingredients) commonly used in the treatment of type 2 diabetes mellitus. These medications mimic the actions of GLP-1, a naturally occurring hormone in the body that helps regulate blood sugar levels.

GLP-1 agonists work by binding to GLP-1 receptors in the pancreas, promoting insulin secretion and inhibiting glucagon release. This mechanism of action leads to improved glucose control, reduced fasting and postprandial blood glucose levels, and decreased hemoglobin A1c levels.

One of the key advantages of GLP-1 agonists is their ability to promote weight loss in patients with type 2 diabetes. These medications slow down gastric emptying, increase satiety, and reduce food intake, resulting in modest but significant weight reduction.

Additionally, GLP-1 agonists have shown cardiovascular benefits, including a reduction in the risk of major adverse cardiovascular events, such as heart attack and stroke. They also exhibit a lower risk of hypoglycemia compared to some other antidiabetic medications.

Some commonly prescribed GLP-1 agonists include exenatide, liraglutide, dulaglutide, and semaglutide. These APIs are typically administered via subcutaneous injection, either once or twice daily, or in some cases, as weekly formulations.

In conclusion, GLP-1 agonists are a valuable class of pharmaceutical APIs used in the management of type 2 diabetes. Their mechanism of action, which includes glucose control, weight loss promotion, and cardiovascular benefits, makes them a favorable choice for patients seeking effective and safe antidiabetic therapy.


Dulaglutide (GLP1 agonists), classified under Anti-diabetics


Anti-diabetics, belonging to the pharmaceutical API (Active Pharmaceutical Ingredient) category, are a group of compounds designed to manage and treat diabetes mellitus, a chronic metabolic disorder characterized by high blood sugar levels. These medications play a vital role in controlling diabetes and preventing complications associated with the disease.

Anti-diabetics encompass a wide range of drug classes, including biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Each class works through different mechanisms to regulate blood sugar levels and improve insulin sensitivity.

Biguanides, such as metformin, reduce glucose production by the liver and enhance insulin sensitivity in peripheral tissues. Sulfonylureas, like glipizide, stimulate insulin secretion from pancreatic beta cells. Thiazolidinediones, including pioglitazone, improve insulin sensitivity in muscle and adipose tissues. DPP-4 inhibitors, such as sitagliptin, increase insulin release and inhibit glucagon secretion. SGLT2 inhibitors, like dapagliflozin, decrease renal glucose reabsorption, leading to increased urinary glucose excretion. GLP-1 receptor agonists, such as exenatide, enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety.

These anti-diabetic APIs serve as the foundational ingredients for the formulation of various oral tablets, capsules, and injectable medications used in the treatment of diabetes. By targeting different aspects of glucose regulation, they help patients achieve and maintain optimal blood sugar levels, thus reducing the risk of diabetic complications, such as cardiovascular disease, neuropathy, and nephropathy.

It is crucial for healthcare professionals to prescribe and administer these anti-diabetic medications appropriately, considering factors like the patient's medical history, co-existing conditions, and potential drug interactions. Regular monitoring of blood glucose levels and close medical supervision are necessary to ensure effective diabetes management.

In conclusion, anti-diabetics form a critical category of pharmaceutical APIs used for the treatment of diabetes. These compounds, encompassing various drug classes, work through distinct mechanisms to regulate blood sugar levels and improve insulin sensitivity. By facilitating glucose control, anti-diabetic APIs help mitigate the risk of complications associated with diabetes mellitus, ultimately promoting better health outcomes for patients.



Dulaglutide manufacturers | traders | suppliers

We have 1 companies offering Dulaglutide produced in 1 different countries.

Get in contact with the supplier of your choice:

  • Senova Technology Co., Ltd. from China, product country of origin China

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.